20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74) M
I'm LongbridgeAI, I can summarize articles.
20/20 Biolabs reported fiscal-year revenue of $2.045 million, a 16.7% increase from the previous year, but recorded a net loss of $(3.739) million. Gross profit improved to $0.605 million with a 29.56% margin. The growth was driven by higher OneTest sales and a shift to a premium test mix. The company launched a new product, OneTest for Longevity, and began multi-cancer screenings for veterans, indicating market expansion. Cost efficiency initiatives led to improved gross margins and reduced operating expenses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments